Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Watson

- PMLiVE

Cellectis gets FDA nod for ‘off-the-shelf’ CAR-T trial

Investigational New Drug gets go-ahead for trials in patients with two haematological cancers

- PMLiVE

Keytruda filed for first- and second-line bladder cancer

Merck & Co hopes to gain advantage over Opdivo and Tecentriq with first-line setting

- PMLiVE

Pfizer mulling product sale to streamline ops; sources

$2bn worth of cardiology, urology and primary care products look likely to be sold off in bulk

- PMLiVE

Opdivo gets FDA green light to treat bladder cancer

BMS adds new US indication to its checkpoint inhibitor

National Institute for Health and Care Excellence NICE logo

NICE set to reject Pfizer’s Ibrance over high cost

Draft guidance on breast cancer therapy calls for more evidence of its benefits

Bristol-Myers Squibb (BMS) building

Opdivo drives growth at BMS, but US sales slow down

Sales beginning to lose momentum despite new indications bringing in $1.3bn for Q4

Pfizer invests in Swedish digital health firm

AMRA's technology transforms MRI images into precise fat and muscle measurements 

Deal Watch December 2016

Allergan, AZ, BMS, Pfizer, Roche and more feature in this month's pharma deals round-up

Strategic symbionts

Strategic alliances are becoming more interesting and more important 

AstraZeneca AZ

AZ tweaks immuno-oncology trials as it chases lung cancer leaders

Toughens targets for durvalumab in NSCLC monotherapy and combination study

Novartis building

Novartis takes biosimilar delay complaint to Supreme Court

Seeks to overturn US law that requires 180-day launch delay after regulatory approval

- PMLiVE

Merck pays Vertex $230m upfront for cancer programmes

Licences four DNA damage and repair programmes with first-in-class or best-in-class potential

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links